Evaluation of potential drug-drug interactions and adverse drug reactions among chronic kidney disease patients: An experience from United Arab Emirates

• Published in: Tropical journal of pharmaceutical research Vol. 21; no. 4; pp. 853 - 861
• Main Authors: Hammoud, Kowsar Mouhib, Sridhar, Sathvik B, Rabbani, Syed Arman, Kurian, Martin Thomas
• Format: Journal Article
• Language: English
• Published: 04.06.2022
• ISSN: 1596-5996; 1596-9827
• DOI: 10.4314/tjpr.v21i4.24

Purpose: To determine the prevalence and assessing nature of potential drug-drug interactions (pDDIs) and adverse drug reactions (ADRs) among chronic kidney disease (CKD) patients.Methods: This was a prospective observational study involving adult CKD patients. Occurrence of pDDIs was evaluated using Micromedex database 2.0. Suspected ADRs during the study period were documented and assessed.Results: Overall prevalence of pDDIs was found to be 85.3 %. A total of 811 pDDIs with 225 different pairs of interacting drugs were identified. Majority of the patients had ≥ 3 pDDIs regardless of type of severity. Thirty-five ADRs were identified in 25 CKD patients. Hyperkalemia was the most-commonly suspected ADR. Logistic regression analysis revealed that age (OR: 1.04, 95 % CI: 1.01 - 107), length of hospital stay (OR: 1.15, 95 % CI: 1.0 - 1.32), presence of comorbidity like diabetes (OR: 9.1, 95 % CI: 3.2 - 25.3) and number of drugs prescribed (OR: 6.88, 95 % CI: 1.5 - 30.0) were positively correlated with occurrence of pDDIs. Length of hospital stay (OR: 1.05, 95 % CI: 0.99 - 1.06) and number of drugs (OR: 0.16, 95 % CI 0.03 - 0.84) were identified as independent predictors of occurrence of ADRs.Conclusion: Prevalence of pDDIs was high in the study population. A majority of the pDDIs were of major severity type, fair documentation grade, and of unspecified onset. A majority of suspected ADRs were probably of moderate in severity and not preventable type.